Alzheimer’s disease CSF biomarkers: clinical indications and rational use
نویسندگان
چکیده
منابع مشابه
Variability of CSF Alzheimer’s Disease Biomarkers: Implications for Clinical Practice
BACKGROUND Cerebrospinal fluid (CSF) biomarkers are increasingly being used for diagnosis of Alzheimer's disease (AD). OBJECTIVE We investigated the influence of CSF intralaboratory and interlaboratory variability on diagnostic CSF-based AD classification of subjects and identified causes of this variation. METHODS We measured CSF amyloid-β (Aβ) 1-42, total tau (t-tau), and phosphorylated t...
متن کاملCSF Biomarkers for Alzheimer's Disease Diagnosis
Alzheimer's disease (AD) is the most common form of dementia that affects several million people worldwide. The major neuropathological hallmarks of AD are the presence of extracellular amyloid plaques that are composed of Abeta40 and Abeta42 and intracellular neurofibrillary tangles (NFT), which is composed of hyperphosphorylated protein Tau. While the amyloid plaques and NFT could define the ...
متن کاملCSF Biomarkers
With an ever growing population of aged individuals who are at risk of developing Alzheimer’s disease (AD), there is an urgent need for a sensitive, specific and preferably non-invasive diagnostic standard of disease progression. Diagnosis of AD is still largely based on exclusion criteria of secondary causes and other forms of dementia with similar clinical pictures, than the diagnostic accura...
متن کاملAmelioration of Symptoms and Biomarkers of Alzheimers Disease by Physical Exercise
Physical exercise advantages have been manifested in several neurodegenerative and/or neuropsychiatric disorders implying that these, largely non-invasive, non-pharmacologic interventions, ought to be examined closely in the Alzheimer’s disease (AD) and other dementias context. Thus, according to the tenets of an increasingly broad consensus, preventative and interventional agents for AD and de...
متن کاملAge and diagnostic performance of Alzheimer disease CSF biomarkers.
OBJECTIVES Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1-42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Acta Neurologica Belgica
سال: 2017
ISSN: 0300-9009,2240-2993
DOI: 10.1007/s13760-017-0816-5